Database

Startups

Main Industry
Health Care
Main Product/Service
i-OBM develops innovative drug formulations using existing active ingredients, focusing on enhancing efficacy, reducing side effects, and extending drug half-life through advanced delivery systems. Their technologies include chelating complex micelles, tr
Founded Year
2011
Unified Business No.
29184891
Status
Active
Number of Employees
0
Total Paid-in Capital
665,890,000 (NT$)
Location of Company
Taiwan , Tainan City
Exit Status
Emerging Stock Exchange(2025)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Introduction
Original BioMedical focuses on developing new drug forms, dosages, and indications without introducing new active ingredients. Their platform can modify a drug’s half-life, enhance efficacy, and reduce side effects, enabling repurposing of existing drugs



More2 ↓

Similar Companies

TAIWAN BIO THERAPEUTICS INC.

Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppre

Acura NanoMedicine Corporation

1. Out-licensing of innovative drug products, including the AN-8 series, a novel therapy designed to reverse cancer drug resistance, and other pharmaceuticals.
2. Utilizing proprietary technology platforms — (1) the HTPVAC drug development platform and (2

Neo-Pharma Biotech Co., Ltd.

Edge AI Solutions
AI Inference Device
DeviceEdge Jetson Series
DeviceEdge AI on ARM Series
AI Inference / Training System
MegaEdge PCIe Series
MegaEdge M.2 Series
MegaEdge MXM Series
AI Inference / Training Server
AI Accelerator & GPU
CoreEdge PCIe Card
I
:::